急性髓系白血病blc—2与bax基因的比值和耐药

目的：了解凋亡抑制基因（Bcl-2)、凋亡诱导基因（Bax)在急性髓系白血病的表达及Bcl-2/Bax比值与耐药关系。方法：用免疫组织化学法检测Bcl-2、Bax抗原表达，细胞培养四氮唑蓝比色法（MTT）药敏试验检测急性髓系白血病（AML）耐药的情况。结果：AML患者Bcl-2高于正常对照组，Ｂax低于正常对照级，其Bcl-2/Bax比值显著高于正常对照组（P＜0．01）。产生耐药组的病例Bcl-2/Bax高于敏感组（P＜0．05），Bcl-2/Bax高比值患者化疗反应差（P＜0．05）。结论：Bcl-2,Bax的异常表达在AML形成、发展和产生耐药起一定作用，检测Bcl-2,Bax比值对治疗药物选择、预后的判断有重要意义。

The Relationship between the Bcl-2/Bax Ratio and Drug Resistance in Acute Myelogenous Leukemia

Objective: To investigate Bcl-2 and Bax gen e expression in acute myelogenous Leukemia and the relationship between Bcl-2/Bax ratio and drug resistance. Method: Expression of Bcl-2 ?Bax was detected by immunohistochemical method while drug resistance of AML wa s detected by cell culture and MTT assay. Results: A high expression of Bcl-2 and a low expression of Bax were detected in AML, respecti vely, and the ratio between Bcl-2 and Bax was significantly higher than that in normal control (P<0.01). The ratio in those who are resistant to chemother apy was significantly higher than that in those sensitive to chemotherapy (P <0.05). The responsiveness to chemotherapy of those with a high ratio was poor er than thos with a low ratio (P<0.05) Conclusion: T he alteration of Bcl-2 and Bax played certain role in the development of drug r esistance in AML, the test of Bcl-2/Bax ratio may have great significance in ch oice of chemotherapeutic agents and also provide important information for outco me prediction.